| Literature DB >> 32397097 |
Yun Zhao1,2,3, Hui Liang1, Shiqiang Zhang1, Shengwei Qu1, Yue Jiang1, Minfang Chen1,2,3.
Abstract
Biodegradable devices for medical applications should be with an appropriate degradation rate for satisfying the various requirements of bone healing. In this study, composite materials of polylactic acid (PLA)/stearic acid-modified magnesium oxide (MgO) with a 1 wt% were prepared through blending extrusion, and the effects of the MgO shapes on the composites' properties in in vitro and in vivo degradation were investigated. The results showed that the long-term degradation behaviors of the composite samples depended significantly on the filler shape. The degradation of the composites is accelerated by the increase in the water uptake rate of the PLA matrix and the composite containing the MgO nanoparticles was influenced more severely by the enhanced hydrophilicity. Furthermore, the pH value of the phosphate buffer solution (PBS) was obviously regulated by the dissolution of MgO through the neutralization of the acidic product of the PLA degradation. In addition, the improvement of the in vivo degrading process of the composite illustrated that the PLA/MgO materials can effectively regulate the degradation of the PLA matrix as well as raise its bioactivity, indicating the composites for utilization as a biomedical material matching the different requirements for bone-related repair.Entities:
Keywords: MgO nanoparticles; MgO whiskers; PLA; biopolymers composites; in vitro degradation; in vivo degradation
Year: 2020 PMID: 32397097 PMCID: PMC7284841 DOI: 10.3390/polym12051074
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Detailed information of the samples.
| Sample | SpMgO Content/PLA Content (w/w) | SwMgO Content/PLA Content (w/w) |
|---|---|---|
| PLA | 0 | 0 |
| PPLA | 1/100 | 0 |
| WPLA | 0 | 1/100 |
Figure 1Schematic illustration of the experiment.
Figure 2SEM microstructures of polylactic acid (PLA) and composites at different degradation times: (a) surface morphologies; (b) fracture morphologies.
Figure 3The (a) weight loss, (b) water intake and (c) pH value as a function of the degradation time of the neat PLA and composite immersed in the phosphate buffer solution (PBS).
Gel permeation chromatography (GPC) data corresponding to the samples.
| Time/Months | PLA | PPLA | WPLA | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
| PI |
|
| PI |
|
| PI | |
| 3 | 135,777 | 85,630 | 1.59 | 124,969 | 79,492 | 1.57 | 142,721 | 87,717 | 1.63 |
| 4 | 122,638 | 78,164 | 1.57 | 119,200 | 74,087 | 1.61 | 128,695 | 78,720 | 1.63 |
| 5 | 113,343 | 70,064 | 1.62 | 105,310 | 65,020 | 1.62 | 111,342 | 75,066 | 1.48 |
| 6 | 84,728 | 55,543 | 1.53 | 77,485 | 50,884 | 1.52 | 103,873 | 67,122 | 1.55 |
| 8 | 51,364 | 28,036 | 1.83 | 64,290 | 41,053 | 1.57 | 68,602 | 44,645 | 1.54 |
| 12 | 4017 | 3365 | 1.22 | 9798 | 16,703 | 1.70 | 21,573 | 13,011 | 1.66 |
Weight averaged molecular weight (M), number averaged molecular weight (M) and dispersity indexes (PI = M/M) of the specimens as determined by GPC.
Figure 4The differential scanning calorimetry (DSC) curves of the secondary heating curves obtained for the degraded samples.
DSC data corresponding to the samples.
| Time(Months)/Samples | Δ | Δ | ||||
|---|---|---|---|---|---|---|
| 3 | PLA | 153.9 | - | −12.8 | 25.5 | 40.8 |
| PPLA | 147.7 | 155.2 | −8.37 | 35.3 | 46.6 | |
| WPLA | 151.7 | 154.5 | −23.6 | 37.7 | 65.4 | |
| 4 | PLA | 151.5 | 156.6 | −21.0 | 33.1 | 57.8 |
| PPLA | 147.6 | 155.2 | −10.9 | 37.5 | 51.6 | |
| WPLA | 149.4 | 154.2 | −22.1 | 34.3 | 60.2 | |
| 5 | PLA | 151.4 | 156.8 | −25.0 | 29.6 | 58.4 |
| PPLA | 147.3 | 155.1 | −6.3 | 38.9 | 48.4 | |
| WPLA | 149.1 | 155.1 | −22.1 | 30.6 | 56.2 | |
| 6 | PLA | 147.2 | 154.7 | −5.0 | 39.6 | 47.6 |
| PPLA | 146.8 | 154.9 | −5.9 | 43.0 | 52.2 | |
| WPLA | 148.8 | 154.8 | −30.3 | 32.9 | 67.5 | |
| 8 | PLA | 149.4 | 155.6 | −26.5 | 45.6 | 77.1 |
| PPLA | 147.7 | 154.6 | −4.8 | 35.8 | 43.3 | |
| WPLA | 147.1 | 154.9 | −16.8 | 43.0 | 63.8 | |
| 12 | PLA | 126.9 | - | −33.0 | 24.9 | 61.9 |
| PPLA | 137.5 | 147.2 | −6.8 | 28.7 | 38.0 | |
| WPLA | 140.6 | 148.9 | −4.0 | 43.1 | 50.3 | |
Figure 5Histological morphologies of the implanted PLA and WPLA after 3-, 6-, 12- and 18-months duration of implantation.